Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for TXG.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 3.016M
March 31, 2026 -8.417M
December 31, 2025 2.242M
September 30, 2025 0.617M
June 30, 2025 3.522M
March 31, 2025 0.422M
December 31, 2024 4.517M
September 30, 2024 0.156M
June 30, 2024 4.603M
March 31, 2024 1.638M
December 31, 2023 5.613M
September 30, 2023 4.374M
June 30, 2023 7.096M
March 31, 2023 -3.414M
Date Value
December 31, 2022 5.001M
September 30, 2022 2.039M
June 30, 2022 6.36M
March 31, 2022 2.417M
December 31, 2021 8.903M
September 30, 2021 6.683M
June 30, 2021 16.19M
March 31, 2021 3.518M
December 31, 2020 7.706M
September 30, 2020 486.97M
June 30, 2020 8.051M
March 31, 2020 -33.82M
December 31, 2019 -1.107M
September 30, 2019 415.64M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Twist Bioscience Corp. 3.787M
Alamar Biosciences, Inc. (California) 201.84M
Personalis, Inc. 7.988M
Adaptive Biotechnologies Corp. 142.19M
Tempus AI, Inc. 97.65M